Loading…
Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. It offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. Its products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $67M | $14M | $9M | $-3M | 24.5% | 23.7% | 322.1% |
| 2024 | $54M | $4M | $2M | $5M | 6.9% | 16.8% | -69.9% |
| 2023 | $46M | $11M | $7M | $4M | 22.4% | 9.6% | 54.7% |
| 2022 | $42M | $7M | $5M | $-3M | 18.0% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 42.04 | 46.09 | 53.84 | 66.59 |
| Operating Revenue | - | 43.01 | 47.17 | 55.24 | 68.09 |
| Cost Of Revenue | - | 28.91 | 33.34 | 39.29 | 47.08 |
| Gross Profit | - | 13.13 | 12.75 | 14.55 | 19.51 |
| Operating Expense | - | 7.97 | 6.99 | 7.38 | 8.82 |
| Research And Development | - | 2.98 | 2.80 | 3.19 | 3.64 |
| Selling General And Administration | - | 4.99 | 4.18 | 4.19 | 5.18 |
| Total Expenses | - | 36.88 | 40.33 | 46.67 | 55.90 |
| Operating Income | - | 5.16 | 5.76 | 7.17 | 10.69 |
| Total Operating Income As Reported | - | 5.12 | 5.76 | 7.17 | 10.69 |
| EBITDA | - | 6.88 | 10.82 | 4.35 | 14.13 |
| Normalized EBITDA | - | 5.96 | 6.91 | 8.48 | 12.01 |
| EBIT | - | 6.16 | 9.96 | 3.19 | 12.89 |
| Interest Income | - | 0.08 | 0.29 | 0.14 | 0.08 |
| Interest Expense | - | 0.46 | 0.53 | 0.56 | 0.83 |
| Net Interest Income | - | -0.39 | -0.24 | -0.41 | -0.75 |
| Other Income Expense | - | 0.92 | 3.90 | -4.12 | 2.12 |
| Interest Income Non Operating | - | 0.08 | 0.29 | 0.14 | 0.08 |
| Interest Expense Non Operating | - | 0.46 | 0.53 | 0.56 | 0.83 |
| Net Non Operating Interest Income Expense | - | -0.39 | -0.24 | -0.41 | -0.75 |
| Pretax Income | - | 5.69 | 9.43 | 2.63 | 12.06 |
| Tax Provision | - | 1.12 | 2.35 | 0.51 | 3.08 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0.18 | 0.98 | -0.79 | 0.54 |
| Net Income Continuous Operations | - | 4.57 | 7.07 | 2.13 | 8.98 |
| Net Income From Continuing And Discontinued Operation | - | 4.57 | 7.07 | 2.13 | 8.98 |
| Net Income From Continuing Operation Net Minority Interest | - | 4.57 | 7.07 | 2.13 | 8.98 |
| Net Income | - | 4.57 | 7.07 | 2.13 | 8.98 |
| Net Income Common Stockholders | - | 4.57 | 7.07 | 2.13 | 8.98 |
| Net Income Including Noncontrolling Interests | - | 4.57 | 7.07 | 2.13 | 8.98 |
| Normalized Income | - | 3.83 | 4.15 | 5.46 | 7.40 |
| Diluted NI Availto Com Stockholders | - | 4.57 | 7.07 | 2.13 | 8.98 |
| Basic Average Shares | - | 3.64 | 3.57 | 3.50 | 3.29 |
| Diluted Average Shares | - | 3.76 | 3.64 | 3.57 | 3.36 |
| Reconciled Depreciation | - | 0.73 | 0.86 | 1.16 | 1.24 |
| Reconciled Cost Of Revenue | - | 28.91 | 33.34 | 39.29 | 47.08 |
| Total Unusual Items | - | 0.92 | 3.90 | -4.12 | 2.12 |
| Total Unusual Items Excluding Goodwill | - | 0.92 | 3.90 | -4.12 | 2.12 |
| Special Income Charges | 0 | -0.04 | 0 | - | - |
| Gain On Sale Of Security | - | 0.96 | 3.90 | -4.12 | 2.12 |
| General And Administrative Expense | - | 4.90 | 4.03 | 4.07 | 4.84 |
| Other Gand A | - | 4.90 | 4.03 | 4.07 | 4.84 |
| Gain On Sale Of Ppe | 0 | -0.04 | 0 | - | - |
| Selling And Marketing Expense | - | 0.09 | 0.16 | 0.12 | 0.34 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Pro-Dex, Inc.this co. | PDEX | $214M | 23.83 | 5.84 | 24.5% | 16.29 |
| Fulcrum Therapeutics, Inc. | FULC | $225M | - | 0.64 | -21.5% | - |
| Foghorn Therapeutics Inc. | FHTX | $220M | -2.96 | -2.02 | 68.5% | -2.28 |
| Inhibikase Therapeutics, Inc. | IKT | $219M | -4.54 | 1.27 | -27.9% | -1.50 |
| Voyager Therapeutics, Inc. | VYGR | $219M | -1.83 |
| - |
| - |
| - |
| - |
| 1.12 |
| -61.1% |
| -1.49 |
| Utah Medical Products, Inc. | UTMD | $216M | 19.17 | 1.82 | 9.5% | 9.09 |
| Keros Therapeutics, Inc. | KROS | $213M | 2.45 | 0.70 | 28.7% | -0.83 |
| RxSight, Inc. | RXST | $211M | -5.42 | 0.77 | -14.1% | -5.68 |
| Atrium Therapeutics, Inc. | RNA | $210M | -2.74 | 1.02 | -37.0% | 0.73 |
| Peer Median | - | -2.74 | 0.89 | -17.8% | -1.49 | |